Study summary
Sotatercept cut death, transplant or hospitalization by three-quarters in high-risk PAH
17.4%died, had a lung transplant or were hospitalized, vs 54.7% with placebo
What was tested
Sotatercept, an injection every 3 weeks that rebalances growth signals in the lung blood vessels, against placebo, added to maximal background therapy, for adults with high-risk pulmonary arterial hypertension.
What they found
- Death, lung transplant or PAH hospitalization occurred in 17.4% vs 54.7% (hazard ratio 0.24).
- Deaths were 8.1% vs 15.1%; transplants 1.2% vs 7.0%.
- Nosebleeds and small dilated blood vessels (telangiectasia) were the most common side effects.
What it means
Stopped early for benefit; the first PAH drug to show fewer deaths and transplants in high-risk people.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.